Tau is essential to β-amyloid-induced neurotoxicity
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Senile plaques and neurofibrillary tangles, the two hallmark lesions of Alzheimer's disease, are the results of the pathological deposition of proteins normally present throughout the brain. Senile plaques are extracellular deposits of fibrillar β-amyloid peptide (Aβ); neurofibrillary tangles represent intracellular bundles of self-assembled hyperphosphorylated tau proteins. Although these two lesions are often present in the same brain areas, a mechanistic link between them has yet to be established. In the present study, we analyzed whether tau plays a key role in fibrillar Aβ-induced neurite degeneration in central neurons. Cultured hippocampal neurons obtained from wild-type, tau knockout, and human tau transgenic mice were treated with fibrillar Aβ. Morphological analysis indicated that neurons expressing either mouse or human tau proteins degenerated in the presence of Aβ. On the other hand, tau-depleted neurons showed no signs of degeneration in the presence of Aβ. These results provide direct evidence supporting a key role for tau in the mechanisms leading to Aβ-induced neurodegeneration in the central nervous system. In addition, the analysis of the composition of the cytoskeleton of tau-depleted neurons suggested that the formation of more dynamic microtubules might confer resistance to Aβ-mediated neurodegeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These observations support the idea that Aβ and Tau act together and that Aβ is upstream of Tau [114,115], positioning Aβ as the initiator and Tau as the executor in the pathogenetic process [116].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [115]
In the citing paper
“Indeed, Tau has been implicated in the synaptotoxicity induced by Aβ exposure [102].”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [102]
In the citing paper
“Thus, cultured neurons from tau knockout (Tau−/−) mice are not susceptible to Aβ-induced synaptic damage and neurotoxicity (Rapoport et al., 2002; Nussbaum et al., 2012; Zempel et al., 2013) or to Aβ-induced defects in axonal transport (Vossel et al., 2011).”
From Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in Tau−/− mice (2017) · cites this paper as Rapoport et al., 2002
In the citing paper
“Neurons without tau are resistant to Aβ toxicity, and APP transgenic mice lacking tau develop Aβ pathology but remain cognitively normal (Rapoport et al., 2002; Roberson et al., 2007).”
From CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease (2018) · cites this paper as Rapoport et al., 2002
In the citing paper
“Data from cell and animal models show that tau is also a mediator of Aβ-induced toxicity46–48.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [46]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Assay of proteins in the presence of interfering materials
Bensadoun, A., & Weinstein, D. (1976) · Analytical Biochemistry · doi:10.1016/s0003-2697(76)80064-4 · Cited by 3,179
Growth of a rat neuroblastoma cell line in serum-free supplemented medium.
Bottenstein, J. E., & Sato, G. H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.1.514 · Cited by 2,276
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.4044 · Cited by 1,459
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324
Research works printed but not linked: 2
- M P Vitek, C G Rasool, F de Sauvage, S M Vitek, R T Bartus, B Beer, R A Ashton, A F Macq, J M Maloteaux, A J Blume Brain Res 464, 121–131 (1988).
- J G Wood, S S Mirra, N L Pollock, L I Binder Proc Natl Acad Sci USA 508, 320–324 (1986).
Cited by
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
“In both cellular and mouse models, extensive data now suggest that the neurotoxicity of Ab is in considerable part dependent on expression of human tau (Rapoport et al, 2002; Jin et al, 2011; Roberson et al, 2011).”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Role of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005
Roles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Increased hippocampal neurogenesis in Alzheimer's disease
Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., & Greenberg, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2634794100 · Cited by 971
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
“Thus, tau may affect microtubule stability by a mechanism independent of tubulin binding, although reports regarding the levels of acetylated tubulin in tau knockout mice vary (Perez et al., 2009; Rapoport et al., 2002).”
BackgroundJin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836
“Indeed, it has already been reported that the suppression or deletion of tau has a profound protective effect against brain damage and neurological deficits (Rapoport et al., 2002; SantaCruz et al., 2005; Roberson et al., 2007; Miao et al., 2010; Shipton et al., 2011; Bi et al., 2017).”
BackgroundCaspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831
Self-citationThe amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
“While, there is some cell work suggesting that Ab toxicity is dependent on tau expression (Rapoport et al. 2002) and elegant transgenic work showing that tau expression can modulate Ab toxicity (Roberson et al. 2007), we have no idea what the pathway between the two molecules is as yet (Mudher and…”
BackgroundTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
“…upstream of changes in Tau, but conversely Tau is considered necessary for the progression of neurodegeneration, as seen in cell and animal models (Rapoport et al., 2002; King et al., 2006; Roberson et al., 2007), and indeed the Tau pathology correlates well with clinical symptoms (Braak and…”
BackgroundAnimal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654
“A variety of mechanisms have been proposed to explain how tau reduction might prevent A toxicity, ranging from altered microtubule stability (Rapoport et al., 2002; Liu et al., 2004; King et al., 2006), elimination of a toxic tau fragment (Park and Ferreira, 2005), regulation of neuronal activity…”
BackgroundPost-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 641
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Kirkitadze, M. D., Bitan, G., & Teplow, D. B. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10328 · Cited by 585
Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 553
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543
Self-citationBennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
Wu, T., Dejanovic, B., Gandham, V. D., Gogineni, A., Edmonds, R., Schauer, S., Srinivasan, K., Huntley, M. A., Wang, Y., Wang, T.-M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.060 · Cited by 466
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Tau phosphorylation: physiological and pathological consequences
Stoothoff, W. H., & Johnson, G. V. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.017 · Cited by 442
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Tau association with synaptic vesicles causes presynaptic dysfunction
Zhou, L., McInnes, J., Wierda, K., Holt, M., Herrmann, A. G., Jackson, R. J., Wang, Y.-C., Swerts, J., Beyens, J., Miskiewicz, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15295 · Cited by 434
Tau, tangles, and Alzheimer's disease
Binder, L. I., Guillozet-Bongaarts, A. L., Garcia-Sierra, F., & Berry, R. W. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.014 · Cited by 434
Self-citationAlzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
The Role of Tau in Alzheimer's Disease and Related Disorders
Medeiros, R., Baglietto‐Vargas, D., & LaFerla, F. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00177.x · Cited by 432
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Nussbaum, J. M., Schilling, S., Cynis, H., Silva, A., Swanson, E., Wangsanut, T., Tayler, K., Wiltgen, B., Hatami, A., Rönicke, R., et al. (2012) · Nature · doi:10.1038/nature11060 · Cited by 427
NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications
Skovronsky, D. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 425
Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease
Lee, G., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Do, L. H., Andreadis, A., Van Hoesen, G., & Ksiezak-Reding, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414
Brain amyloid-β oligomers in ageing and Alzheimer’s disease
Lesné, S. E., Sherman, M. A., Grant, M., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Ashe, K. H. (2013) · Brain · doi:10.1093/brain/awt062 · Cited by 409
GSK-3 is essential in the pathogenesis of Alzheimer's disease
Takashima, A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s335 · Cited by 396
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Ricciarelli, R., & Fedele, E. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170116143743 · Cited by 380
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
GSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease
Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., Ward, S., Reyes, J. F., Philibert, K., Glucksman, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237974 · Cited by 357
Self-citationSoluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases
Ferreira, S. T., Vieira, M. N. N., & De Felice, F. G. (2007) · IUBMB Life · doi:10.1080/15216540701283882 · Cited by 335
GSK3: a possible link between beta amyloid peptide and tau protein
Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.011 · Cited by 327
Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326
Mouse models of Alzheimer's disease
Hall, A. M., & Roberson, E. D. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.017 · Cited by 317
Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation
Shipton, O. A., Leitz, J. R., Dworzak, J., Acton, C. E. J., Tunbridge, E. M., Denk, F., Dawson, H. N., Vitek, M. P., Wade-Martins, R., Paulsen, O., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2610-10.2011 · Cited by 315
“This suggests that tau protein is one element required for the synaptotoxic effects of A 1– 42 , consistent with the finding that tau-depleted neurons do not degenerate in the presence of A (Rapoport et al., 2002).”
InfluentialSelf-citationTau pathophysiology in neurodegeneration: a tangled issue
Spires-Jones, T. L., Stoothoff, W. H., de Calignon, A., Jones, P. B., & Hyman, B. T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.11.007 · Cited by 315
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 309
Chronic stress and glucocorticoids: From neuronal plasticity to neurodegeneration
Vyas, S., Rodrigues, A. J., Silva, J. M., Tronche, F., Almeida, O. F. X., Sousa, N., & Sotiropoulos, I. (2016) · Neural Plasticity · doi:10.1155/2016/6391686 · Cited by 297
Autophagic degradation of tau in primary neurons and its enhancement by trehalose
Krüger, U., Wang, Y., Kumar, S., & Mandelkow, E.-M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.009 · Cited by 297
Atwood, C. S., Obrenovich, M. E., Liu, T., Chan, H., Perry, G., Smith, M. A., & Martins, R. N. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00174-7 · Cited by 293
Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110190 · Cited by 292
VDAC1, mitochondrial dysfunction, and Alzheimer’s disease
Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286
Development of tau aggregation inhibitors for alzheimer's disease
Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286
Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283
Self-citationDendritic Tau in Alzheimer’s Disease
Ittner, A., & Ittner, L. M. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.003 · Cited by 278
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
Role of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Stein, T. D., Anders, N. J., DeCarli, C., Chan, S. L., Mattson, M. P., & Johnson, J. A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2211-04.2004 · Cited by 277
Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., Lanté, F., & Buisson, A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4261-13.2014 · Cited by 272
“In the context of AD, recent studies have shown that synaptotoxicity driven by A o exposure relies on the presence of tau (Rapoport et al., 2002; Roberson et al., 2007; Ittner et al., 2010).”
BackgroundJevtovic-Todorovic, V, Absalom, A. R., Blomgren, K., Brambrink, A., Crosby, G., Culley, D. J., Fiskum, G., Giffard, R. G., Herold, K. F., Loepke, A. W., et al. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet177 · Cited by 269
Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice
Ittner, A., Chua, S. W., Bertz, J., Volkerling, A., van der Hoven, J., Gladbach, A., Przybyla, M., Bi, M., van Hummel, A., Stevens, C. H., et al. (2016) · Science · doi:10.1126/science.aah6205 · Cited by 263
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Chang, C.-W., Shao, E., & Mucke, L. (2021) · Science · doi:10.1126/science.abb8255 · Cited by 263
“However, ablation or reduction of endogenous, nonaggregated WT tau prevents or diminishes Ab toxicity in cultures of rodent primary neurons (130), as well as several (but not all) synaptic, network, and cognitive alterations in different lines of APP transgenic mice (22, 44, 51, 131, 132).”
BackgroundPark, S.-Y., & Ferreira, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1125-05.2005 · Cited by 262
Self-citationSotiropoulos, I., Catania, C., Pinto, L. G., Silva, R., Pollerberg, G. E., Takashima, A., Sousa, N., & Almeida, O. F. X. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0730-11.2011 · Cited by 257
Mitochondria and Calcium in Alzheimer’s Disease: From Cell Signaling to Neuronal Cell Death
Calvo-Rodriguez, M., & Bacskai, B. J. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.004 · Cited by 254
Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation
Chu, T.-T., Gao, N., Li, Q.-Q., Chen, P.-G., Yang, X.-F., Chen, Y.-X., Zhao, Y.-F., & Li, Y.-M. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.02.016 · Cited by 247
The involvement of microRNAs in neurodegenerative diseases
Maciotta, S., Meregalli, M., & Torrente, Y. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00265 · Cited by 245
Chemotactic Signaling, Microglia, and Alzheimer's Disease Senile Plaques: Is There a Connection?
Luca, M. (2003) · Bulletin of Mathematical Biology · doi:10.1016/s0092-8240(03)00030-2 · Cited by 243
Huang, Y., Weisgraber, K. H., Mucke, L., & Mahley, R. W. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:189 · Cited by 242
Kelly, B. L., & Ferreira, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605081200 · Cited by 241
Self-citationMolecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 241
Human secreted tau increases amyloid-beta production
Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230
“In vitro and in vivo models show Ab induced neurotoxicity and Ab induced axonal transport deficits are ameliorated by dose-dependent reductions in tau (Rapoport et al., 2002; Vossel et al., 2010).”
Tau-Mediated Cytotoxicity in a Pseudohyperphosphorylation Model of Alzheimer's Disease
Fath, T., Eidenmüller, J., & Brandt, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09733.2002 · Cited by 227
Amyloid β-Protein Toxicity and the Pathogenesis of Alzheimer Disease
Yankner, B. A., & Lu, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800018200 · Cited by 227
Reynolds, C. H., Garwood, C. J., Wray, S., Price, C., Kellie, S., Perera, T., Zvelebil, M., Yang, A., Sheppard, P. W., Varndell, I. M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709715200 · Cited by 226
The H1c haplotype at the MAPT locus is associated with Alzheimer's disease
Myers, A. J., Kaleem, M., Marlowe, L., Pittman, A. M., Lees, A. J., Fung, H. C., Duckworth, J., Leung, D., Gibson, A., Morris, C. M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi241 · Cited by 222
Tau alteration and neuronal degeneration in tauopathies: mechanisms and models
Brandt, R., Hundelt, M., & Shahani, N. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.018 · Cited by 221
Mechanisms of n-3 fatty acid-mediated development and maintenance of learning memory performance
Su, H.-M. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.11.003 · Cited by 221
Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid
King, M. E., Kan, H.-M., Baas, P. W., Erisir, A., Glabe, C. G., & Bloom, G. S. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200605187 · Cited by 217
Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease
Horowitz, P. M., Patterson, K. R., Guillozet-Bongaarts, A. L., Reynolds, M. R., Carroll, C. A., Weintraub, S. T., Bennett, D. A., Cryns, V. L., Berry, R. W., & Binder, L. I. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1988-04.2004 · Cited by 215
Self-citationBehavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 213
Atypical, non-standard functions of the microtubule associated Tau protein
Sotiropoulos, I., Galas, M.-C., Silva, J. M., Skoulakis, E., Wegmann, S., Maina, M. B., Blum, D., Sayas, C. L., Mandelkow, E.-M., Mandelkow, E., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0489-6 · Cited by 213
Kanaan, N. M., Pigino, G. F., Brady, S. T., Lazarov, O., Binder, L. I., & Morfini, G. A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.003 · Cited by 212
Self-citationBurke, W. (2004) · NeuroToxicology · doi:10.1016/s0161-813x(03)00090-1 · Cited by 211
Park, S.-Y., Kim, H.-S., Cho, E.-K., Kwon, B.-Y., Phark, S., Hwang, K.-W., & Sul, D. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.05.030 · Cited by 209
Metadata
- Authors
- Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A.
- Affiliations
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-04-16
- Volume
- 99
- Issue
- 9
- Pages
- 6364-6369
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC122954
- OpenAlex
- W2081768153
- Cited by
- 807
- References
- 45
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 22 · 2023: 24 · 2022: 22 · 2021: 25 · 2020: 44 · 2019: 37 · 2018: 40 · 2017: 43 · 2016: 39 · 2015: 40 · 2014: 55 · 2013: 44 · 2012: 51
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag015383-02)
- National Institute on Aging (AG15383)
- National Institute of Neurological Disorders and Stroke (R01NS039080, NS 39080)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau protein, amyloid-beta, Alzheimer's disease, neurotoxicity, neurite degeneration, hippocampal neurons, microtubules, cytoskeleton, amyloid plaques, neurofibrillary tangles, amyloid fibrils
- MeSH terms
- Animals, Brain, Central Nervous System, Cytoskeleton, Hippocampus, Humans, Immunohistochemistry, Mice, Transgenic, Microtubules, Phenotype, Immunoblotting, Blotting, Western, Amyloid beta-Peptides, tau Proteins, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.